1.General Specification(in stock)
(1)API(Pure powder)
(2)Tablet
(3)Capsule
(4)Injection
(5)Liquid Drops
2.Customization:
We will negotiate individually, OEM/ODM, No brand, for secience researching only.
Internal Code:BM-3-094
GLP-1 CAS 87805-34-3
Main market: USA, Australia, Brazil, Japan, Germany, Indonesia, UK, New Zealand , Canada etc.
Analysis: HPLC, LC-MS, HNMR
Technology support: R&D Dept.-4
We provide GLP-1 Injection, please refer to the following website for detailed specifications and product information.
https://www.bloomtechz.com/oem-odm/injection/glp-1-injections.html
Geli Pharmaceutical's GLP-1 new drug ASC30 has achieved phase II clinical success in the United States
On March 10, 2026, Geli Pharmaceutical Co., Ltd. (Hong Kong Stock Exchange code: 1672, abbreviated as "Geli") announced that its small molecule GLP-1 receptor (GLP-1 R) agonist ASC30 subcutaneous depot formulation for the treatment of obesity related internet disorder in the United States, a 24 week study (NCT06679959), achieved positive top line results. A total of 65 subjects were enrolled in three cohorts, and two formulations (A1 and A2) were administered. All subjects were obese subjects or overweight subjects with at least one weight related complication, The Chuan phase study achieved its primary endpoint, with patients receiving 3 doses (once a month) of ASC30 subcutaneous reservoir formulation A1 showing a statistically significant (compared to placebo, p<0.05) and clinically significant mean weight gain of 6.3% (after placebo adjustment) at week 12.
In addition, ASC30 subcutaneous storage formulation A1 showed a statistically significant (compared to placebo, p<0.05) and clinically significant average weight loss of 7.5% (after placebo correction) at 16 weeks of pen administration once a month for a total of 3 doses.
ASC30 is a small molecule GLP-1R agonist currently undergoing clinical research, with unique and differentiated properties that make it possible for the same small molecule to be used for both oral tablets and subcutaneous injection. ASC30 is a new chemical entity (NCE) with US and global compound patent protection, with a patent protection period until 2044 (excluding potential patent extensions).
Lilly invests $3 billion to increase its supply chain layout in China
On March 11, 2026, Eli Lilly announced plans to invest a total of $3 billion over the next decade to comprehensively expand its supply chain capacity in China, build a local production and supply system for oral solid preparations, and focus on expanding the production capacity of the first registered oral small molecule GLP-1 receptor agonist, orforglipron. This investment is another important measure for Lilly to deepen its cultivation in China and support the development of local healthcare industry. Lilly China has submitted the marketing application of orforqlipron for the treatment of type 2 diabetes and obesity to the State Drug Administration at the end of 2025. As an important part of this round of investment, Lilly plans to work with multiple local partners to plan and layout future pipeline large-scale production capacity, including orforglipron. Lilly announced a strategic partnership with Kanglong Chemical, with an expected investment of 200 million US dollars and support for its technological capacity building. The scale will gradually expand in the future depending on development.
This investment will adopt a combination of internal expansion and external cooperation: on the one hand, relying on the technological and talent advantages of the Lilly Suzhou factory, we will strengthen production capacity coordination; On the other hand, we cooperate with multiple local production partners to release incremental production capacity. This investment is expected to significantly increase supply, while meeting the medication needs of Chinese patients and creating value for local industry development, economic growth, and employment. Orforge lipon is a small molecule (non peptide) glucagon like peptide-1 receptor agonist (GLP-1 RA) that is currently under development and administered orally once daily. This medication can be taken at any time of the day without restrictions on diet and water intake. This drug was discovered by Chugai Pharmaceutical Co., Ltd. and authorized for development by Eli Lilly in 2018.